ABSTRACT
Lymphedema is one of the most frequent side effects following cancer treatment, and treatment opportunities for it are currently lacking. Stem cell therapy has been proposed as a possible novel treatment modality. This study was the first case in which freshly isolated adipose-derived stromal cells were used to treat lymphedema. Treatment was given as a cell-assisted lipotransfer in which 4.07 3 10 7 cells were injected with 10 ml of lipoaspirate in the axillary region. Four months after treatment, the patient reported a great improvement in daily symptoms, reduction in need for compression therapy, and volume reduction of her affected arm. There were no adverse events. The outcome for this patient provides support for the potential use of cellular therapy for lymphedema treatment. We have begun a larger study to further test the feasibility and safety of this procedure (ClinicalTrials. gov Identifier NCT02592213). STEM CELLS TRANSLATIONAL MEDICINE 2016;5:857-859
SIGNIFICANCE
Lymphedema is a very debilitating side effect of cancer treatment and has very few treatment options. Stem cell therapy has the potential to change the treatment paradigm from a conservative to a more curative approach. Freshly isolated, autologous, adipose-derived stromal cells were combined with a fat-graft procedure to treat lymphedema. The treated patient had great improvement in daily symptoms, a reduced need for compression therapy, and a reduction in arm volume after
INTRODUCTION
In the developed world, cancer treatment is the leading cause of lymphedema. It is a debilitating condition associated with recurrent infections [1] and reduced quality of life [2, 3] . The present standard of care is compression therapy, which depends on continuous adherence to be effective [4] . Accordingly, new therapeutic approaches are needed to treat this condition. One such approach is stem cell therapy; in a recent review, we summarized all preclinical and clinical studies that used stem cells for therapeutic lymphangiogenesis [5] . All reported clinical studies used bone marrow-derived mesenchymal stem cells (MSCs). Adipose tissue is the most abundant and easiest accessible source of MSCs, but it has not been used previously for lymphedema treatment. To our knowledge, we are the first to report the use of cell-assisted lipotransfer using freshly isolated adipose-derived stromal cells (the stromal vascular fraction [SVF]) to treat lymphedema.
MATERIALS AND METHODS
The patient was a 48-year-old woman with breast cancer-related lymphedema of her arm due to lymphadenectomy and radiation therapy 4 years ago. Besides conservative management, there were no treatment opportunities available; therefore, she was offered experimental stem cell treatment, which she accepted. Hospital exemption was acquired from the Danish Health and Medicines Authority to allow for the autologous cell treatment. No further approvals were necessary.
The procedure was performed under general anesthesia and involved liposuction (bodyjet; Human med AG, Schwerin, Germany, http:// www.humanmed.com) of 320 ml of lipoaspirate Departments of a Plastic and Reconstructive Surgery and b Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark for SVF isolation using the automated Celution 800/CRS System (Cytori Therapeutics, San Diego, CA, http://www.cytori.com) according to the manufacturer's instructions. The SVF was isolated within 2 hours and resuspended in 5 ml of lactated Ringer's solution with a syringe, and 1 ml was saved for characterization. An additional 10 ml of pure centrifuged lipoaspirate was used for fat grafting to the axillary region using a technique incorporating fan-shaped injections to release axillary scar formation. The remaining 4 ml of SVF was injected into the same region in the subcutaneous plane immediately after isolation at 8 premarked points. Figure 1 presents intraoperative photographs. The patient was discharged the same afternoon.
As previously described by Haahr et al. [6] , SVF was characterized by nucleated cell count and viability, the percentage of fibroblastoid colony-forming units (CFU-F), and surface marker analysis using the following markers from BD Biosciences (Albertslund, Denmark, http://www.bd.com): anti-CD34 (PE-CF594, clone 581), anti-CD45 (fluorescein isothiocyanate, clone HI30), CD31 (Alexa Fluor 647, clone WM59), CD73 (allophycocyanin [APC], clone AD2), CD90 (APC, clone 5E10), and appropriate isotypes according to the manufacturer's recommendations. Sample acquisition was performed on a BD LSRII flow cytometer and analyzed using the FACSDiva software version 8.0.1 (BD Biosciences) and FlowJo 7.6.5 (Tree Star, Ashland, OR, http://www.flowjo.com). Cell doublets were excluded from all analyses by sequential gating through forwardand side-scatter height/width plots. A nucleated cell count including viability analysis was performed using three technical replicates with a NucleocounterNC-200 (ChemoMetec, Allerod, Denmark, http://chemometec.com). The percentage of CFU-F was determined by seeding cells at low density (4 concentrations in triplicate ranging from 28 to 280 live nucleated cells per cm 2 ) in Dulbecco's Modified Eagle's Medium (Sigma-Aldrich, St. Louis, MO, http://www.sigmaaldrich.com) with 1 g/l glucose, 10% fetal bovine serum (Sigma-Aldrich), 1% penicillin-streptomycin (PS) (Sigma-Aldrich), culturing for 14 days, and counting hematoxylinstained colonies comprising more than 50 cells.
The outcome was evaluated by pre-and postoperative circumference measurements, dual-energy x-ray absorptiometry (DXA) scans, and evaluation of adverse events. DXA scans were performed as whole-body scans and each arm was measured separately; based on known densities of bone, fat, and nonfat tissue, a volume was calculated as described in the literature [7] . Adverse events were evaluated immediately following the SVF injection, before discharge, and after 1 and 4 months with a combination of clinical examination of the injected area, openended questioning (experience of any discomfort) of the patient, and more specific questioning regarding infection, pain, and swelling.
RESULTS
A total of 4.07 3 10 7 viable cells were administered to the patient. The CFU-F was 0.7%. Flow cytometry on stored, fixed cells showed that cells were 14.3% CD451, 60.4% CD341, 9.6% CD311, 44.5% CD731, and 69.5% CD901.
The patient was seen after 1 and 4 months, and she reported a great reduction in her symptoms of arm heaviness and tension. The patient no longer needed to use intermittent pneumatic compression therapy, which she had used on a daily basis before treatment. She still wore her compression garment.
Circumference measurements after 4 months showed a reduction of 1 cm at the wrist and lower arm and 2 cm at the upper arm. Pre-and postoperative DXA scans showed a reduction of 292 ml in the lymphedema-affected arm, whereas that of the healthy arm was increased by 50 ml. There were no postoperative complications or adverse events related to the procedure. 
DISCUSSION
Treatment of lymphedema remains one of the greatest challenges in reconstructive surgery for which efficient treatment possibilities are lacking. The outcome of this patient supports the results of previous studies using bone marrow-derived cells and provides a foundation for the potential use of cellular therapy for lymphedema treatment [8, 9] .
The DXA scan was performed as a whole-body scan. Software limitations meant that the arm-volume measurements included the shoulder, thereby increasing the risk for variability in the volume measurements. This could explain the increase of 50 ml in the healthy arm volume at follow-up. To minimize variability, we now scan each arm separately and isolate the arm with subregional analysis, a technique that was not available to us when this patient was scanned. Potential changes in lymph drainage were not assessed in this patient, and this is a limitation when interpreting the results, because we cannot conclude that the cell therapy resulted in improved lymph drainage. We recommend that all future studies seeking to treat lymphedema include standardized, subjective evaluations with validated questionnaires and scales, objective measurements of arm volume through circumference measurements and imaging studies, and functional measurements to evaluate any change in drainage.
Based on the promising preclinical and clinical results, we have initiated a phase II study in our department to further test the feasibility and safety of this procedure (ClinicalTrials.gov Identifier: NCT02592213).
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